we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
1 The study included people from the US Komodo Research database (January 1, 2016 to January 31, 2025) aged 45 years and started treatment with Wegovy or tirzepatide on or after May 13, 2022
Clinical trials have demonstrated that tirzepatide may reduce the risk of cardiovascular events, such as heart attacks and strokes
Molecular bases of VEGFR-2-mediated physiological function and pathological role
High potassium levels can be dangerous, so its important to have regular blood tests to monitor your potassium levels
Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy